Lv3
330 积分 2023-10-10 加入
Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
16天前
已完结
Structural basis of anti-PD-L1 monoclonal antibody avelumab for tumor therapy
16天前
已完结
Looking for the Optimal PD-1/PD-L1 Inhibitor in Cancer Treatment: A Comparison in Basic Structure, Function, and Clinical Practice
16天前
已完结
Small Molecule Agents Targeting PD-1 Checkpoint Pathway for Cancer Immunotherapy: Mechanisms of Action and Other Considerations for Their Advanced Development
16天前
已完结
TOP1-DNA Trapping by Exatecan and Combination Therapy with ATR Inhibitor
26天前
已完结
基于基因修饰细胞系的生物检定法研究进展
2个月前
已完结
Avelumab: combining immune checkpoint inhibition and antibody-dependent cytotoxicity
2个月前
已完结
AQbD理念下的《中华人民共和国药典》与ICH Q2分析方法验证指导原则解析与实例探讨
3个月前
已完结
Bioassay Development for Bispecific Antibodies—Challenges and Opportunities
4个月前
已完结
Microbial Transglutaminase Estimation in Enzyme‐treated Surimi‐Based Products by Enzyme Immunosorbent Assay
6个月前
已完结
皖公网安备34019202002308
